Author

Chiara Falzarano

Institute of Oncology Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alberto Jesus. ArribasiD· 1 shared Alessandro Ghiringhelli· 1 shared Alex ZadroiD· 1 shared Andrea RinaldiiD· 1 shared Eleonora CannasiD· 1 shared Emanuela Lovati· 1 shared Francesca GuidettiiD· 1 shared Francesco BertoniiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alberto Jesus. ArribasORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma Cells

Giulio Sartori, Alessandro Ghiringhelli, Eleonora Cannas, Francesca Guidetti, Alberto Jesus. Arribas, Alex Zadro, Luciano Cascione, Chiara Falzarano, Martina Imbimbo, Matteo Moretti, Andrea Rinaldi, Emanuela Lovati, Francesco Bertoni

This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.

bioRxiv · Dec 25, 2025 · PreprintCancer Biology